Poonam Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.15 Cr
as on 22-12-2024
- Paid Up Capital ₹ 1.12 Cr
as on 22-12-2024
- Company Age 30 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.23 M
as on 22-12-2024
- Revenue 54.48%
(FY 2022)
- Profit 22.47%
(FY 2022)
- Ebitda 15.97%
(FY 2022)
- Net Worth 10.09%
(FY 2022)
- Total Assets 9.07%
(FY 2022)
About Poonam Pharma
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.15 Cr and a paid-up capital of Rs 1.12 Cr.
The company has closed loans amounting to ₹2.23 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mukesh Kumar and Payal Agrawal serve as directors at the Company.
- CIN/LLPIN
U24232WB1994PTC062327
- Company No.
062327
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Mar 1994
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Poonam Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mukesh Kumar  | Director | 16-Jan-1995 | Current |
| Payal Agrawal | Director | 09-Aug-2013 | Current |
Financial Performance of Poonam Pharma.
Poonam Pharma Pvt Ltd, for the financial year ended 2022, experienced significant growth in revenue, with a 54.48% increase. The company also saw a substantial improvement in profitability, with a 22.47% increase in profit. The company's net worth Soared by an impressive increase of 10.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Poonam Pharma?
In 2022, Poonam Pharma had a promoter holding of 90.00% and a public holding of 10.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Maniambar Properties Private LimitedActive 27 years 10 monthsMukesh Kumar and Payal Agrawal are mutual person
Charges (Loans)
₹0
₹0.22 Cr
Charges Breakdown by Lending Institutions
- Others : 0.22 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Dec 2018 | Others | ₹2.23 M | Satisfied |
How Many Employees Work at Poonam Pharma?
Poonam Pharma has a workforce of 13 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Poonam Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Poonam Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
